Researchers are continually exploring ways to overcome drug resistance. One approach involves combining crosslinking agents with other therapies, such as immunotherapy or targeted therapies. Another strategy is the development of new drugs that can either enhance the effectiveness of existing crosslinkers or target different pathways in cancer cells.
